Cetabine, a 6-class generic of Qilu pharmaceutical, has been approved for production
-
Last Update: 2020-04-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
On May 12, the raw materials and injection land of dixitabin developed by Qilu pharmaceutical obtained the production approval issued by the State Food and drug administration Desetabine is a demethylation drug, which belongs to DNA methyltransferase inhibitor In 2006, the product was approved by the FDA of the United States for the treatment of primary and secondary myelopathy syndrome (MDS); in 2008, the imported product of dessicabine was approved by SFDA The drug is the only one in China that can effectively delay the progress of MDS The listing of dixitabin, developed by Qilu pharmaceutical, will bring new hope for MDS patients in China, and will also promote drug research and development in the field of blood tumor
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
